Detalhe da pesquisa
1.
Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.
Blood
; 139(15): 2338-2346, 2022 04 14.
Artigo
Inglês
| MEDLINE | ID: mdl-34936697
2.
The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.
Blood
; 139(3): 384-398, 2022 01 20.
Artigo
Inglês
| MEDLINE | ID: mdl-34232979
3.
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
Haematologica
; 2024 Feb 22.
Artigo
Inglês
| MEDLINE | ID: mdl-38385243
4.
Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy.
Eur J Neurol
; : e16285, 2024 Mar 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38511878
5.
Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study.
Br J Haematol
; 201(2): 256-266, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36740991
6.
Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort.
Br J Haematol
; 202(1): 54-64, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37038217
7.
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.
Blood
; 137(17): 2307-2320, 2021 04 29.
Artigo
Inglês
| MEDLINE | ID: mdl-33211799
8.
Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study.
Cancer
; 128(3): 519-528, 2022 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34605020
9.
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.
Blood
; 135(23): 2041-2048, 2020 06 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32232482
10.
Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.
Blood
; 135(5): 360-370, 2020 01 30.
Artigo
Inglês
| MEDLINE | ID: mdl-31774495
11.
Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study.
Ann Hematol
; 101(2): 317-332, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-34617134
12.
Optimization of whole-body 2-[18F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma.
Eur Radiol
; 32(5): 3085-3096, 2022 May.
Artigo
Inglês
| MEDLINE | ID: mdl-34842956
13.
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
N Engl J Med
; 379(10): 934-947, 2018 09 06.
Artigo
Inglês
| MEDLINE | ID: mdl-30184451
14.
Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.
Blood
; 133(15): 1664-1676, 2019 04 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30782609
15.
Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma.
Am J Hematol
; 96(5): 599-605, 2021 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33661547
16.
A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort.
BMC Public Health
; 21(1): 432, 2021 03 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33653294
17.
Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.
Genet Epidemiol
; 43(7): 844-863, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31407831
18.
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.
N Engl J Med
; 377(13): 1250-1260, 2017 09 28.
Artigo
Inglês
| MEDLINE | ID: mdl-28953447
19.
Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study.
Blood
; 131(22): 2449-2453, 2018 05 31.
Artigo
Inglês
| MEDLINE | ID: mdl-29559480
20.
Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T3 phase IB trial of the LYSA.
Ann Hematol
; 99(8): 1771-1778, 2020 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-32601796